Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 206

Sort by

Sort Order Select

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Comparative Analysis of Oligomonocytic CMML with Myelodysplastic and Myeloproliferative CMML Subtypes: A Study of 849 Molecularly-Annotated Patients

Clifford M. Csizmar, Anuya A. Natu, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle Hammond, Sanam Loghavi, Alexandre Bazinet, Terra L. Lasho, Christy Finke, Aref Al-Kali, Hassan B Alkhateeb, Naseema Gangat, Abhishek A. Mangaonkar, Antoine N. Saliba, Ayalew Tefferi, Guillermo Garcia-Manero, Hagop Kantarjian, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 6747.

https://doi.org/10.1182/blood-2024-209126

Published: 2024

Journal Articles

TP53 mutations and Complex Karyotype in Newly-Diagnosed Blast/Accelerated Phase MPN Are Associated with Ephemeral Response to Treatment with Venetoclax + HMA and Poor Survival

Blood (2024) 144 (Supplement 1): 6657.

https://doi.org/10.1182/blood-2024-193917

Published: 2024

Journal Articles

TP53 -Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors

Kevin Hung, Aref Al-Kali, Carla Toop, Mrinal M. Patnaik, Zoe Price, Taxiarchis Kourelis, Daniel Thomas, Morie A. Gertz, Hossein Anani, Wilson I. Gonsalves, Chung Hoow Kok, Ayalew Tefferi, Devendra Hiwase, Mithun V Shah

Blood (2024) 144 (Supplement 1): 4594.

https://doi.org/10.1182/blood-2024-211931

Published: 2024

Journal Articles

Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials

Maymona Abdelmagid, Jeanne Palmer, Aref Al-Kali, Mehrdad Hefazi, James M. Foran, Kebede Begna, Cecilia Y. Arana Yi, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2024-198757

Published: 2024

Journal Articles

Clinical Characteristics and Prognostic Significance of Co-Mutated SETBP1 / GATA2 Myeloid Neoplasms

Yazan Jabban, Rong He, Kurt Bessonen, Patricia Greipp, Dragan Jevremovic, James M. Foran, Cecilia Y. Arana Yi, Antoine N. Saliba, Mehrdad Hefazi, Aasiya Matin, William J. Hogan, Abhishek A. Mangaonkar, Mrinal M. Patnaik, Mithun V Shah, Hassan B Alkhateeb, Aref Al-Kali

Blood (2024) 144 (Supplement 1): 6700.

https://doi.org/10.1182/blood-2024-201128

Published: 2024

Journal Articles

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance

Blood (2024) 144 (Supplement 1): 244.

https://doi.org/10.1182/blood-2024-210251

Published: 2024

Journal Articles

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica M. Stempel, Luca Lanino, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Stacey M. Frumm, Shougat Barua, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan F Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 664.

https://doi.org/10.1182/blood-2024-208034

Published: 2024

Journal Articles

Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients

Nadia Toumeh, Yazan Jabban, Ahmad Nanaa, Rong He, David Viswanatha, Dragan Jevremovic, James M. Foran, Cecilia Y. Arana Yi, Antoine N. Saliba, Mehrdad Hefazi, William J. Hogan, Mithun V Shah, Abhishek A. Mangaonkar, Mrinal M. Patnaik, Hassan B Alkhateeb, Aref Al-Kali

Blood (2024) 144 (Supplement 1): 2869.

https://doi.org/10.1182/blood-2024-209413

Published: 2024

Journal Articles

Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Blood (2024) 144 (Supplement 1): 2852.

https://doi.org/10.1182/blood-2024-209015

Published: 2024

Journal Articles

Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41 MT Germline Predisposition Syndrome

Yael Kusne, Talha Badar, Terra L. Lasho, Ludovica Marando, Abhishek A. Mangaonkar, Christy Finke, James M. Foran, Aref Al-Kali, Hassan B Alkhateeb, Naseema Gangat, Jeanne Palmer, David Viswanatha, Mark R. Litzow, Animesh D. Pardanani, Ayalew Tefferi, Timothy Chlon, Alejandro Ferrer, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 3183.

https://doi.org/10.1182/blood-2024-202406

Published: 2024

Journal Articles

Targeting Aberrant DLK1 Re-Expression in ASXL1 -Mutant Chronic Myelomonocytic Leukemia with BRD4 / p300-Directed Epigenetic Small Molecule Therapy

Terra L. Lasho, Jenna A. Fernandez, Jeong-Heon Lee, Linh D. Pham, Huihuang Yan, Christy Finke, Abhishek A. Mangaonkar, Aref Al-Kali, Naseema Gangat, Joseph Collard, Claes Wahlestedt, Mrinal M. Patnaik, Moritz Binder

Blood (2024) 144 (Supplement 1): 3197.

https://doi.org/10.1182/blood-2024-204070

Published: 2024

Journal Articles

Preclinical Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Chronic Myelomonocytic Leukemia

Brandon Turunen, Craig Leach, Matthew Smith, Terra L. Lasho, Christy Finke, Abhishek A. Mangaonkar, Aref Al-Kali, Yael Kusne, Talha Badar, James M. Foran, Aisha Margaert, Michelle Baptista, Stephanie Wiltzius, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 2771.

https://doi.org/10.1182/blood-2024-209024

Published: 2024

Journal Articles

A Clinical Overview of Clonal Cytopenia of Undetermined Significance in the Presence of ZRSR2 Mutations

Mahmoud Yacout, Bahga Katamesh, Yazan Jabban, Rong He, Patricia Greipp, Dragan Jevremovic, James M. Foran, Cecilia Y. Arana Yi, Antoine N. Saliba, Abhishek A. Mangaonkar, Mithun V Shah, Mrinal M. Patnaik, Hassan B Alkhateeb, Aref Al-Kali

Blood (2024) 144 (Supplement 1): 2667.

https://doi.org/10.1182/blood-2024-208957

Published: 2024

Journal Articles

Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 3204.

https://doi.org/10.1182/blood-2024-208890

Published: 2024

Journal Articles

Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53- mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series

Talha Badar, Kashish J. Shah, Mobachir El Kettani, James M. Foran, Mohamed A. Kharfan-Dabaja, Hemant S. Murthy, Naseema Gangat, Aref Al-Kali, Mithun V Shah, Hassan B Alkhateeb, Antoine N. Saliba, William J. Hogan, Cecilia Y. Arana Yi, Lisa Sproat, Jeanne Palmer, Mark R. Litzow, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 1823.

https://doi.org/10.1182/blood-2024-203825

Published: 2024

Journal Articles

Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)

Blood (2024) 144 (Supplement 1): 1820.

https://doi.org/10.1182/blood-2024-209193

Published: 2024

Journal Articles

Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform

Ayalew Tefferi, Saubia Fathima, Ali Khalid Alsugair, Clifford M. Csizmar, Mark Gurney, Terra L. Lasho, Christy Finke, Abhishek A. Mangaonkar, Aref Al-Kali, Hassan B Alkhateeb, Kaaren K. Reichard, Animesh D. Pardanani, Naseema Gangat, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 1827.

https://doi.org/10.1182/blood-2024-207736

Published: 2024

Journal Articles

Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome

Blood (2024) 144 (Supplement 1): 440.

https://doi.org/10.1182/blood-2024-203879

Published: 2024

Journal Articles

Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Blood (2024) 144 (Supplement 1): 4247.

https://doi.org/10.1182/blood-2024-204114

Published: 2024

NARROW

Risk prediction for clonal cytopenia: multicenter real-world evidence

Comparative Analysis of Oligomonocytic CMML with Myelodysplastic and Myeloproliferative CMML Subtypes: A Study of 849 Molecularly-Annotated Patients

TP53 mutations and Complex Karyotype in Newly-Diagnosed Blast/Accelerated Phase MPN Are Associated with Ephemeral Response to Treatment with Venetoclax + HMA and Poor Survival

TP53 -Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors

Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials

Clinical Characteristics and Prognostic Significance of Co-Mutated SETBP1 / GATA2 Myeloid Neoplasms

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients

Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41 MT Germline Predisposition Syndrome

Targeting Aberrant DLK1 Re-Expression in ASXL1 -Mutant Chronic Myelomonocytic Leukemia with BRD4 / p300-Directed Epigenetic Small Molecule Therapy

Preclinical Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Chronic Myelomonocytic Leukemia

A Clinical Overview of Clonal Cytopenia of Undetermined Significance in the Presence of ZRSR2 Mutations

Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia

Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53- mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series

Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)

Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform

Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome

Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only